# Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Source: https://onco.cc/trials/nct06957379/  
OnCo record `nct06957379` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Exemestane and Fulvestrant in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.

## Summary

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy is a phase 2 interventional study registered as NCT06957379 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 78 participants enrolled, started 2024-02-29 and due to reach its primary completion in 2025-06. Interventions recorded: Letrozole, Anastrozole, Exemestane, Fulvestrant and Sirolimus for Injection (Albumin-bound).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06957379
- Phase: 2
- Setting: A Phase II Clinical Trial of the Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for the Treatment of HR-positive, HER2-negative Patients With Advanced Breast Cancer Who Have Failed Standard Therapy
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06957379: https://clinicaltrials.gov/study/NCT06957379

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Exemestane](https://onco.cc/drugs/exemestane/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06957379.json